Treating cancer from the inside out®
Game-changing therapies at the forefront of innovation in radiopharmaceutical cancer therapy
About
Perspective Therapeutics is on a mission to transform cancer treatment with targeted alpha particle therapy
Perspective Therapeutics is a radiopharmaceutical company dedicated to developing image-guided, targeted alpha-particle therapies (TATs) for the treatment of cancer.
Technology
Our radioisotope technology delivers radiation at a cellular level
Our revolutionary Pb-212-based alpha-particle radiotherapies are designed to deliver powerful alpha radiation directly to cancer cells utilizing high-affinity targeting peptides.
In contrast to conventional radiotherapy, this approach targets more potent alpha particles directly to tumor cells, delivering significantly higher energy at a shorter range. Due to its short half-life, the rapid decay of Pb-212 leads to potentially greater tumor cell killing while avoiding the emergence of resistance and limiting the damage to healthy tissue.
In addition, our image-guided theranostics platform allows physicians to confirm tumor target expression and off-target distribution prior to treatment to assist with patient selection and optimize outcomes.
Perspective Therapeutics uses proprietary targeting peptides conjugated to radioisotopes via a proprietary Pb-specific chelator to image tumors, and then deliver alpha-particle radiopharmaceuticals to attack them on a cellular level.
Therapy
Therapeutic Areas
Pipeline
Oncology pipeline of image-guided alpha-particle radiotherapies
Most programs leverage the chemically matched isotope pair Pb-203/212 conjugated to high-affinity, tumor-specific peptides for image-guided alpha particle cancer therapies.
| Construct | Target Disease | Phase |
|---|---|---|
| VMT01/02 | Melanoma (MC1R imaging & therapy) | Monotherapy in phase 1/2 and Combination with Nivolumab in early phase 1/2 |
| VMT-α-NET | Neuroendocrine cancers, other SSTR2 expressing tumors | Phase 1/2 |
| PSV359 (FAP) | Multiple solid tumors | First in human therapy |
| PSV40X (small molecule) | Prostate (PSMA imaging & therapy) | Human clinical imaging |
| Other programs (novel peptides) | Solid and hematological tumors | Discovery |
| Pre-targeting platform: Antibodies & Proteins | Multiple solid and hematological tumors | Discovery |
Pipeline
The latest news from Perspective Therapeutics
Events
Jefferies London Healthcare Conference
June 17, 2024
2nd Annual Radiopharmaceutical Innovation
Summit
Press release
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
November 27, 2024